Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
| Revenue (Most Recent Fiscal Year) | $69.65M |
| Net Income (Most Recent Fiscal Year) | $-81.27M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 20.11 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 7.64 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -147.70% |
| Net Margin (Trailing 12 Months) | -147.74% |
| Return on Equity (Trailing 12 Months) | -49.53% |
| Return on Assets (Trailing 12 Months) | -37.78% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.53 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.38 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 8.94 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.96 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.32 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.91 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.17 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 108.40M |
| Free Float | 103.85M |
| Market Capitalization | $1.62B |
| Average Volume (Last 20 Days) | 2.31M |
| Beta (Past 60 Months) | 2.40 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 61.91% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |